Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP)
Post# of 721
(Total Views: 248)
Posted On: 11/14/2018 6:05:40 PM
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Grows Stronger with Patents and Third-Party Partners
- Improving the quality, taste and effectiveness of cannabis products with DehydraTECH
- Recently granted two new U.S. patents, with over 50 additional patent applications filed worldwide
- Applications span a wide range of products as the company out-licenses IP to third-party partners through a royalty model
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is using its DehydraTECH to increase the quality, taste and effectiveness of cannabis products. Lexaria’s revolutionary drug delivery platform is disrupting the way cannabidiol enters the bloodstream. Rather than relying on the traditional methods of inhalation, which has harmful lasting impact on a person’s health, DehydraTECH allows for a safer, more efficient means of ingestion. This edible technology increases the bioavailability of the drug, amplifying intestinal absorption by 5-10 times. It allows for a more controlled dosage, masks the bitter medicinal taste without the use of sugar and reduces the amount of time it takes to experience the desired effect.
DehydraTECH is patented for CBD and all other non-psychoactive cannabinoids, as well as for THC and psychoactive cannabinoids. The implications of these patents reach beyond cannabinoids, naming a broad range of lipophilic bioactives and food/carrier particles. The company recently announced that it has been granted two new U.S. patents related to certain cannabinoid-infused beverage compositions (http://nnw.fm/o6UZB). Currently, the company has over 50 patent applications filed worldwide.
Lexaria complements companies desiring to improve existing or create new products. The company can partner with the drug industry and enhance consumer products manufactured by partner companies. DehydraTECH is out-licensed to third-party partners through an affordable royalty model and is available in more than 40 countries where DehydraTECH is patented or patent-pending.
While Lexaria is currently focused on utilizing its technology in the medical and recreational cannabis, nicotine and NSAID industries, it has applications across a wide range of products. DehydraTECH has been used in processed foods, beverages, vitamins, pain relievers, smoking cessation and more.
John Docherty, president of Lexaria, shares an overview of how this technology and business model work in a short video found here: http://nnw.fm/Dez84.
For more information, visit the company’s website at www.LexariaBioscience.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Improving the quality, taste and effectiveness of cannabis products with DehydraTECH
- Recently granted two new U.S. patents, with over 50 additional patent applications filed worldwide
- Applications span a wide range of products as the company out-licenses IP to third-party partners through a royalty model
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is using its DehydraTECH to increase the quality, taste and effectiveness of cannabis products. Lexaria’s revolutionary drug delivery platform is disrupting the way cannabidiol enters the bloodstream. Rather than relying on the traditional methods of inhalation, which has harmful lasting impact on a person’s health, DehydraTECH allows for a safer, more efficient means of ingestion. This edible technology increases the bioavailability of the drug, amplifying intestinal absorption by 5-10 times. It allows for a more controlled dosage, masks the bitter medicinal taste without the use of sugar and reduces the amount of time it takes to experience the desired effect.
DehydraTECH is patented for CBD and all other non-psychoactive cannabinoids, as well as for THC and psychoactive cannabinoids. The implications of these patents reach beyond cannabinoids, naming a broad range of lipophilic bioactives and food/carrier particles. The company recently announced that it has been granted two new U.S. patents related to certain cannabinoid-infused beverage compositions (http://nnw.fm/o6UZB). Currently, the company has over 50 patent applications filed worldwide.
Lexaria complements companies desiring to improve existing or create new products. The company can partner with the drug industry and enhance consumer products manufactured by partner companies. DehydraTECH is out-licensed to third-party partners through an affordable royalty model and is available in more than 40 countries where DehydraTECH is patented or patent-pending.
While Lexaria is currently focused on utilizing its technology in the medical and recreational cannabis, nicotine and NSAID industries, it has applications across a wide range of products. DehydraTECH has been used in processed foods, beverages, vitamins, pain relievers, smoking cessation and more.
John Docherty, president of Lexaria, shares an overview of how this technology and business model work in a short video found here: http://nnw.fm/Dez84.
For more information, visit the company’s website at www.LexariaBioscience.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LXRPD) Stock Research Links
Scroll down for more posts ▼